Biological E's JE vaccine gets WHO nod
City-based biotech firm Biological E achieved a major milestone when World Health Organization (WHO) had awarded prequalification for global use in...
City-based biotech firm Biological E achieved a major milestone when World Health Organization (WHO) had awarded prequalification for global use in adults of the company's Japanese Encephalitis vaccine. The firm is hopeful that the world body will also prequalify the vaccine for pediatric use by the year-end.
Biological E has developed the vaccine in partnership with Europe's Valneva. Based on Valneva's JEV technology, the vaccine, which was successfully launched recently, is being marketed in India under the trade name JEEV and commercialization in other JE-endemic countries is currently under process.
This is the first prequalification of a JE vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries, the company said in a statement. "We are happy that our JE vaccine is the first ever WHO prequalified JE vaccine. It is an extremely important achievement for the vaccines community as our vaccine's prequalification is well in time to support GAVI's plans of introducing the JE vaccine in several developing countries," said Mahima Datla, Managing Director, Biological E Limited.
Thomas Lingelbach, Valneva's President and Chief Executive Officer, said: "We share the excitement for this great achievement and are pleased that our technology used for Ixiaro will now help introducing an excellent vaccine in countries of substantial needs," he added.
Biological E emerged as a fast growing company. Recently, it entered into a five year Pentavalent supply arrangement with GAVI. Besides, the biotech firm also formed a joint venture with GlaxoSmithKline (GSK) to create a six-in-one pediatric vaccine combining GSK's IPV and BioE's pentavalent vaccine.